Curated for Orthogate.org Members

CLINICAL OVERVIEW

Shoulder Innovations has announced FDA 510(k) clearance and the nationwide commercial launch of the N-22™ Humeral Head implant, engineered specifically for patients suffering from metal hypersensitivity undergoing anatomic total shoulder arthroplasty (TSA). Fabricated from biocompatible titanium alloy with advanced surface treatment, the N-22™ Humeral Head complements the company's previously cleared N-22™ Glenosphere for reverse shoulder arthroplasty (RTSA), providing surgeons with a complete hypoallergenic ecosystem across the InSet™ Shoulder System platform. The design addresses the estimated 10% to 15% of the surgical population exhibiting allergic sensitivities to cobalt, chromium, or nickel.

Metal hypersensitivity remains an under-recognized contributor to unexplained persistent pain, synovitis, osteolysis, and aseptic loosening in total joint arthroplasty. Conventional anatomic humeral head components predominantly utilize cobalt-chromium-molybdenum (CoCrMo) alloys due to their historic wear characteristics against ultra-high-molecular-weight polyethylene (UHMWPE). However, ionic shedding and immune-mediated delayed-type hypersensitivity (type IV) can precipitate chronic pain and implant compromise in sensitized individuals. The N-22™ Humeral Head solves this clinical challenge by incorporating high-purity titanium alloy architecture paired with proprietary surface finishing, virtually eliminating nickel and cobalt exposure while optimizing articulation dynamics against InSet™ glenoid constructs.

By pairing low-wear titanium surface engineering with the proven bone-preserving fixation of the InSet™ glenoid platform, the system restores physiological glenohumeral biomechanics while shielding immunologically sensitive patients from reactive ionic wear cascades.

REGULATORY & EVIDENCE PATHWAY

• Regulatory Basis: Cleared via FDA 510(k) premarket notification following comprehensive tribological wear testing, cyclic fatigue testing exceeding physiological shoulder demand cycles, and surface characterization benchmarks validating articulation against crosslinked polyethylene.
• Supporting Evidence: In-vitro simulator data confirm wear rates substantially equivalent to conventional cobalt-chromium (CoCr) articulating bearings without cytotoxic metallic ion leaching into periprosthetic tissues.
• Key Data Points: Taper engagement and cyclic fatigue evaluations demonstrated construct endurance through 10 million cycles under extreme eccentric loads without fretting corrosion, complementing the January 2026 clearance of the N-22™ Glenosphere to establish an end-to-end metal-safe shoulder arthroplasty portfolio.

SURGICAL WORKFLOW IMPACT

The N-22™ Humeral Head integrates directly into the established Shoulder Innovations InSet™ instrumentation platform, utilizing standard sizing gauges, trial heads, and taper engagement mechanics. Operative workflow requires zero additional learning curve or specialized tooling: humeral preparation, resection sizing, and taper impaction proceed identically to standard cobalt-chrome head insertion.

This direct interchangeability streamlines institutional inventory and eliminates the need for separate surgical trays when treating metal-allergic patients. Ambulatory surgery centers (ASCs) and hospital sterile processing departments can seamlessly manage inventory without expanding physical tray footprint or extending operative room turnover times.

COMPETITIVE LANDSCAPE

Historically, surgeons managing severe metal hypersensitivity in shoulder arthroplasty were restricted to ceramic heads (such as CeramTec Biolox options) or off-label configurations with limited size offerings and high cost premiums. Ceramic options carry inherent risks of catastrophic brittle fracture, while surface-coated metallic implants may experience delamination under repetitive shear stresses.

The N-22™ platform directly competes against ceramic alternatives and coated systems by offering ductile shatter-resistance, standard surgical tactile feedback, and seamless integration with the InSet™ glenoid fixation design. Its comprehensive size matrix allows precise anatomical reconstruction without the cost hurdles and handling restrictions of ceramic components.

CLINICAL SIGNIFICANCE FOR ORTHOGATE MEMBERS

For attending shoulder arthroplasty specialists, the N-22™ Humeral Head resolves an acute clinical dilemma without compromising biomechanical stability or requiring complex instrumentation changes. Given that patch testing demonstrates metal sensitivity in up to 15% of arthroplasty candidates, having an on-shelf, anatomically matched titanium option ensures comprehensive surgical coverage for high-risk immunological patients.

Sources:

• OrthoSpineNews: Shoulder Innovations Receives FDA 510(k) Clearance for N-22™ Humeral Head and Initiates Full Commercial Launch
• FDA 510(k) Premarket Notification Database